Overexpression of the PD-L1 in tumor is associated with a worse prognosis across numerous tumor histologies, making PD-1/PD-L1 immunomodulatory axis attractive for the therapeutic intervention (Wang et al., 2016). The gene discussed is CD274; the disease is neoplasm.